BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544-1553. [PMID: 23152524 DOI: 10.1128/jvi.02294-12] [Cited by in Crossref: 116] [Cited by in F6Publishing: 56] [Article Influence: 12.9] [Reference Citation Analysis]
Number Citing Articles
1 Li Z, Liu Y, Zhang Y, Shao X, Luo Q, Guo X, Lin G, Cai Q, Zhao Z, Chong Y. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. Biomed Res Int 2017;2017:9849823. [PMID: 29164151 DOI: 10.1155/2017/9849823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Aissa Larousse J, Trimoulet P, Recordon Pinson P, Tauzin B, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia. Virol J 2015;12:84. [PMID: 26047611 DOI: 10.1186/s12985-015-0318-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
3 Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep 2018;8:8988. [PMID: 29895871 DOI: 10.1038/s41598-018-26862-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
4 Jabara CB, Hu F, Mollan KR, Williford SE, Menezes P, Yang Y, Eron JJ, Fried MW, Hudgens MG, Jones CD, Swanstrom R, Lemon SM. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. Antimicrob Agents Chemother 2014;58:6079-92. [PMID: 25092699 DOI: 10.1128/AAC.03466-14] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
5 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Fajardo A, Soñora M, Cristina J, Hernández N, Moreno P. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Dis Markers 2018;2018:2514901. [PMID: 30186532 DOI: 10.1155/2018/2514901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Howe JA, Long J, Black S, Chase R, McMonagle P, Curry S, Thompson S, DiNubile MJ, Howe AY. Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin. Open Forum Infect Dis 2014;1:ofu078. [PMID: 25734146 DOI: 10.1093/ofid/ofu078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
7 Babcock GJ, Iyer S, Smith HL, Wang Y, Rowley K, Ambrosino DM, Zamore PD, Pierce BG, Molrine DC, Weng Z. High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLoS One 2014;9:e100325. [PMID: 24956119 DOI: 10.1371/journal.pone.0100325] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
8 Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants. Antimicrob Agents Chemother 2015;59:7548-57. [PMID: 26392483 DOI: 10.1128/AAC.01444-15] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Kliemann DA, Tovo CV, da Veiga ABG, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol 2016; 22(40): 8910-8917 [PMID: 27833382 DOI: 10.3748/wjg.v22.i40.8910] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
10 Khan HU, Khan S, Shah MA, Attaullah S, Malik MA. Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients. PLoS One 2020;15:e0231480. [PMID: 32275694 DOI: 10.1371/journal.pone.0231480] [Reference Citation Analysis]
11 Hunyady B, Abonyi M, Gerlei Z, Gervain J, Horváth G, Jancsik V, Lengyel G, Makkai E, Pár A, Péter Z, Pusztay M, Ribiczey P, Rókusz L, Sarrazin C, Schneider F, Susser S, Szalay F, Tornai I, Tusnádi A, Újhelyi E, Werling K, Makara M. Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy. Clin Exp Hepatol 2018;4:83-90. [PMID: 29904724 DOI: 10.5114/ceh.2018.75957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Haseltine EL, De Meyer S, Dierynck I, Bartels DJ, Ghys A, Davis A, Zhang EZ, Tigges AM, Spanks J, Picchio G, Kieffer TL, Sullivan JC. Modeling viral evolutionary dynamics after telaprevir-based treatment. PLoS Comput Biol 2014;10:e1003772. [PMID: 25101970 DOI: 10.1371/journal.pcbi.1003772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
13 Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 2014;58:2781-97. [PMID: 24590484 DOI: 10.1128/AAC.02386-13] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 5.9] [Reference Citation Analysis]
14 Berger KL, Scherer J, Ranga M, Sha N, Stern JO, Quinson AM, Kukolj G. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. Antimicrob Agents Chemother 2015;59:6017-25. [PMID: 26195509 DOI: 10.1128/AAC.00932-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
15 Chen SR, Wang AQ, Lin LG, Qiu HC, Wang YT, Wang Y. In Vitro Study on Anti-Hepatitis C Virus Activity of Spatholobus suberectus Dunn. Molecules 2016;21:E1367. [PMID: 27754461 DOI: 10.3390/molecules21101367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
16 Han B, Parhy B, Lu J, Hsieh D, Camus G, Martin R, Svarovskaia ES, Mo H, Dvory-Sobol H. In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir. J Clin Microbiol 2019;57:e01844-18. [PMID: 30728196 DOI: 10.1128/JCM.01844-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
17 Nishiya AS, de Almeida-Neto C, Ferreira SC, Alencar CS, Di-Lorenzo-Oliveira C, Levi JE, Salles NA, Mendrone A Jr, Sabino EC. HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, Brazil. PLoS One 2014;9:e86413. [PMID: 24466079 DOI: 10.1371/journal.pone.0086413] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
18 Chui CK, Dong WW, Joy JB, Poon AF, Dong WY, Mo T, Woods CK, Beatty C, Hew H, Harrigan PR, Brumme CJ. Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. J Clin Microbiol 2015;53:2942-50. [PMID: 26135875 DOI: 10.1128/JCM.00650-15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
19 颜学兵. 抗HCV是否步入以DAA为主的特异性治疗时代? 世界华人消化杂志 2016; 24(13): 1943-1951 [DOI: 10.11569/wcjd.v24.i13.1943] [Reference Citation Analysis]
20 Abdel-Hameed EA, Rouster SD, Ji H, Ulm A, Hetta HF, Anwar N, Sherman KE, Shata MT. Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy. Viral Immunol 2016;29:252-8. [PMID: 26885675 DOI: 10.1089/vim.2015.0093] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
21 Dietz J, Rupp D, Susser S, Vermehren J, Peiffer KH, Filmann N, Bon D, Kuntzen T, Mauss S, Grammatikos G, Perner D, Berkowski C, Herrmann E, Zeuzem S, Bartenschlager R, Sarrazin C. Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS One 2016;11:e0156731. [PMID: 27281344 DOI: 10.1371/journal.pone.0156731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
22 Wu R, Geng D, Chi X, Wang X, Gao X, Xu H, Shi Y, Guan Y, Wang Y, Jin J, Ding Y, Niu J. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect Drug Resist. 2019;12:2987-3015. [PMID: 31571951 DOI: 10.2147/idr.s218584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Hirotsu Y, Kanda T, Matsumura H, Moriyama M, Yokosuka O, Omata M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol Int. 2015;9:424-430. [PMID: 25791176 DOI: 10.1007/s12072-015-9624-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
24 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
25 Larrat S, Kulkarni O, Claude JB, Beugnot R, Blum MG, Fusillier K, Lupo J, Tremeaux P, Plages A, Marlu A, Duborjal H, Signori-Schmuck A, Francois O, Zarski JP, Morand P, Leroy V. Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients. J Clin Microbiol 2015;53:389-97. [PMID: 25411182 DOI: 10.1128/JCM.02547-14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. Clin Mol Hepatol. 2017;23:51-56. [PMID: 28297836 DOI: 10.3350/cmh.2016.0053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
27 Eslam M, George J. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? Hepatol Int. 2015;9:5-8. [PMID: 25788373 DOI: 10.1007/s12072-014-9600-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 2015;65:50-3. [PMID: 25766988 DOI: 10.1016/j.jcv.2015.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
29 Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS One. 2015;10:e0134395. [PMID: 26317755 DOI: 10.1371/journal.pone.0134395] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
30 Kirst ME, Li EC, Wang CX, Dong HJ, Liu C, Fried MW, Nelson DR, Wang GP. Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients. PLoS One 2013;8:e69698. [PMID: 23922778 DOI: 10.1371/journal.pone.0069698] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
31 Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
32 Raj VS, Hundie GB, Schürch AC, Smits SL, Pas SD, Le Pogam S, Janssen HLA, de Knegt RJ, Osterhaus ADME, Najera I, Boucher CA, Haagmans BL. Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients. Sci Rep 2017;7:4688. [PMID: 28680115 DOI: 10.1038/s41598-017-04931-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
33 Li Z, Zhang Y, Liu Y, Shao X, Luo Q, Cai Q, Zhao Z. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China. Medicine (Baltimore) 2017;96:e6830. [PMID: 28489763 DOI: 10.1097/MD.0000000000006830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
34 Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310. [PMID: 26842909 DOI: 10.1038/srep20310] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 11.6] [Reference Citation Analysis]
35 Costa VD, Brandão-Mello CE, Nunes EP, Dos Santos Silva PGC, de Souza Rodrigues LLLX, Lampe E, do Amaral Mello FC. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes. PLoS One 2019;14:e0216327. [PMID: 31063475 DOI: 10.1371/journal.pone.0216327] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
36 Margeridon-Thermet S, Le Pogam S, Li L, Liu TF, Shulman N, Shafer RW, Najera I. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing. PLoS One. 2014;9:e105569. [PMID: 25140696 DOI: 10.1371/journal.pone.0105569] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
37 Malta F, Gaspareto KV, Lisboa-Neto G, Carrilho FJ, Mendes-Correa MC, Pinho JRR. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect Dis 2017;17:716. [PMID: 29132303 DOI: 10.1186/s12879-017-2817-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
38 Eltahla AA, Leung P, Pirozyan MR, Rodrigo C, Grebely J, Applegate T, Maher L, Luciani F, Lloyd AR, Bull RA. Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. Sci Rep 2017;7:41719. [PMID: 28139734 DOI: 10.1038/srep41719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
39 Gane EJ, Metivier S, Nahass R, Ryan M, Stedman CA, Svarovskaia ES, Mo H, Doehle B, Dvory-Sobol H, Hedskog C, Lin M, Brainard DM, Yang JC, McHutchison JG, Sulkowski M, Younes Z, Lawitz E. The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment. Hepatol Commun 2017;1:538-49. [PMID: 29404477 DOI: 10.1002/hep4.1060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
40 Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother 2013;57:6236-45. [PMID: 24100495 DOI: 10.1128/AAC.01578-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
41 Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. Virol J 2015;12:186. [PMID: 26577836 DOI: 10.1186/s12985-015-0414-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
42 Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sassera D, De Marco L, Girello A, Mondelli MU, Baldanti F. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017;7:16017. [PMID: 29167469 DOI: 10.1038/s41598-017-15987-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
43 Zhang Y, Cao Y, Zhang R, Zhang X, Lu H, Wu C, Huo N, Xu X. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients. PLoS One 2016;11:e0165658. [PMID: 27812165 DOI: 10.1371/journal.pone.0165658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
44 Zhou K, Liang Z, Wang C, Hu F, Ning C, Lan Y, Tang X, Tucker JD, Cai W. Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China. PLoS One 2016;11:e0157438. [PMID: 27341031 DOI: 10.1371/journal.pone.0157438] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
45 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
46 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
47 Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20(11): 2902-2912 [PMID: 24659881 DOI: 10.3748/wjg.v20.i11.2902] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
48 Gupta N, Wu CH, Wu GY. Secondary Structural Elements of the HCV X-region Involved in Viral Replication. J Clin Transl Hepatol 2015;3:1-8. [PMID: 26356238 DOI: 10.14218/JCTH.2015.00003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Sun D, Dai M, Shen S, Li C, Yan X. Analysis of naturally occurring resistance-associated variants to NS3/4A protein inhibitors, NS5A protein inhibitors and NS5B polymerase inhibitors in patients with chronic hepatitis C. Gene Expr. 2017;. [PMID: 29221500 DOI: 10.3727/105221617x15100607143377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
50 Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA. Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses 2015;7:5206-24. [PMID: 26426038 DOI: 10.3390/v7102868] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
51 Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. J Clin Microbiol. 2015;53:2195-2202. [PMID: 25926499 DOI: 10.1128/JCM.03633-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
52 Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
53 de Leuw P, Stephan C. Protease inhibitors for the treatment of hepatitis C virus infection. GMS Infect Dis 2017;5:Doc08. [PMID: 30671330 DOI: 10.3205/id000034] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
54 Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Böcher WO, Datsenko Y, Steinmann G, Scherer J, Stern JO. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother. 2014;58:698-705. [PMID: 24217701 DOI: 10.1128/aac.01976-13] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
55 Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients. Virol J. 2013;10:355. [PMID: 24341898 DOI: 10.1186/1743-422x-10-355] [Cited by in Crossref: 58] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
56 Jiang M, Zhang EZ, Ardzinski A, Tigges A, Davis A, Sullivan JC, Nelson M, Spanks J, Dorrian J, Nicolas O. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. Antimicrob Agents Chemother. 2014;58:5456-5465. [PMID: 24982088 DOI: 10.1128/aac.03052-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]